Cervical Cancers
44
13
19
13
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 44 trials
100.0%
+13.5% vs benchmark
9%
4 trials in Phase 3/4
15%
2 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (44)
Nurse-led Primary Healthcare Intervention Model in Women's Health Management in Hong Kong
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
Negative HPV Test Results on Infinity/GeneXpert® With the Presence of a Late Amplification Signal: What Does This Mean ? (PaPCR)
GYNecologic Cancer-Related COGnitive Impairment
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
IDOV-Immune for Advanced Solid Tumors
The Effect of Motivational Interviewing on HPV-DNA Testing
Validation of a Lab-free Low-cost Screening Test for Prevention of Cervical Cancer
Advancing Cervical Cancer Screening Through the Emergency Department - IIS
Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors
Toripalimab for High-risk Locally Advanced Cervical Cancer
A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent Chemoradiotherapy in Cervical Cancer Patients With Positive Lymph Nodes After Surgery: A Multicenter Randomized Controlled Clinical Trial
Self-sampling for HPV Screening
The Effects of Immunonutrition Therapy on Locally Advanced Cervical Cancer Patients
A Study to Investigate the Prevalence of Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ and Characterize the Clinicopathologic Features of Gynecologic Cancers in Taiwan
Use Misoprostol to Optimize Prevention of Cervical Cancer
Primary HPV Self-Collection in Indonesia
Sexual Health Integration in Treatment of Gynecological Oncology
Ivonescimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy Followed by Type A Hysterectomy in Stage IB2 and IIA1 Cervical Cancer
Emergence of Bacterial Resistance to Antibiotics in the Digestive Microbiota of Patients Treated With Anticancer Drugs